[Safety and efficacy of immune checkpoint inhibitors in elderly patients]. / Tolérance et efficacité des inhibiteurs de points de contrôle immunitaire en monothérapie chez les patients âgés.
Bull Cancer
; 110(11): 1204-1214, 2023 Nov.
Article
em Fr
| MEDLINE
| ID: mdl-37679205
ABSTRACT
Immune checkpoint inhibitors (ICI) are the standard of care for many solid tumors with specific physiopathology mechanisms and adverse events. While the percentage of elderly patients increase from years to years, these patients are underrepresented in clinical trials. Immunosenescence and inflammaging, two main components of the aging of our immune system, and their consequences on the safety and the efficacy are today major focus of clinical research. However, there are still no risk assessment score specific to ICI in elderly patients. In this review we showed the global reassuring data on safety from several retrospective and subgroup analysis, in elderly patients. In summary, impairment of the general state is an independent factor of occurrence of adverse events treatment related whatever the age. Here, we highlight the necessity to use of geriatric evaluation screening test in clinic, the need of specific risk score ICI use in the erdely population and mostly the inclusion of elderly patients in clinical trial to generate specific data.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Contexto em Saúde:
1_ASSA2030
/
2_ODS3
Problema de saúde:
1_doencas_nao_transmissiveis
/
2_muertes_prematuras_enfermedades_notrasmisibles
Assunto principal:
Imunossenescência
/
Neoplasias
Tipo de estudo:
Clinical_trials
/
Risk_factors_studies
Limite:
Aged
/
Humans
Idioma:
Fr
Revista:
Bull Cancer
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
França